Elevated Rate Pacing of Cardiac Amyloidosis

Purpose

This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.

Conditions

  • Cardiac Amyloidosis
  • Pacemaker

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults 18 and older - Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee - Implanted Cardiac Pacemaker (+/- Defibrillator) - Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation - Non-dilated left ventricle by echocardiography - Ability to provide written consent - English Speaking

Exclusion Criteria

  • Paced QRS duration of >150 ms (indicator for pacing mediated dyssynchrony) - Dilated left ventricle

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Supportive Care
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Elevated Pacemaker Rate 		CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.
  • Other: Pacemaker Rate
    CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.

Recruiting Locations

University of Minnesota
Minneapolis, Minnesota 55455
Contact:
Meghan Muscala
612-626-5863
payne324@umn.edu

More Details

Status
Recruiting
Sponsor
University of Minnesota

Study Contact

Meghan Muscala
612-626-5863
payne324@umn.edu